

Využitie AI pri MR diagnostike karcinómu prostaty

MUDr. Vít'azoslav Belan, PhD.

Úvod

2012 - ESUR - MR prostaty PIRADS (Prostate Imaging Reporting and Data System)

2019 – EAU: MR prostaty pred biopsiou

2022 – potenciál pre skríning karcinómu prostaty (CaP)

2022 – EU rezolúcia rozšírenie skríningu nádorov vrátane CaP (zahrňujúca MR prostaty)

P. Puech: How should we prepare a generation of radiologists for MRI-based prostate cancer screening? European Radiology, <https://doi.org/10.1007/s00330-023-09680-3>

Válek V (2022) Council recommendation of 9 December 2022 on strengthening prevention through early detection: a new EU approach on cancer screening. Off J Eur Union. C473:01

Úvod


- Kvalifikácia, certifikácia rádiológov a zobrazovacích centier
- Dvojité čítanie
- Využitie AI (umelej inteligencie) v MR prostaty

European Radiology (2021) 31:9567–9578
<https://doi.org/10.1007/s00330-021-08021-6>

UROGENITAL



ESUR/ESUI position paper: developing artificial intelligence for precision diagnosis of prostate cancer using magnetic resonance imaging

Tobias Penzkofer^{1,2}  · Anwar R. Padhani³ · Baris Turkbey⁴ · Masoom A. Haider⁵ · Henkjan Huisman⁶ · Jochen Walz⁷ · Georg Salomon⁸ · Ivo G. Schoots^{9,10} · Jonathan Richenberg¹¹ · Geert Villeirs¹² · Valeria Panebianco¹³ · Olivier Rouviere^{14,15} · Vibeke Berg Logager¹⁶ · Jelle Barentsz⁶



MRI Centres:



PET/CT Centre:



CT Centre:



Multimodality Centre:



Nuclear medicine:





Densitometry:




TUR (11/2017). PSA 5,52ng/ml, PSAD = 0.13ng/ml².

36x54x42mm (APxLLxCC), volume cca 42.5ml


mpMR 1200 images




Prostate Imaging Reporting and Data System (PI-RADS)



Radiology Assistant




Transrectal vs Transperineal Biopsy Approaches



Chang DT, Challacombe B, Lawrentschuk N. Nat Rev Urol. 2013;10:690-702.

Pitfall I – Reader experience



Kasivisvanathan NEJM 20128

ESOI Webinar 1, 01/31, 2019

HP Schlemmer, J. Radtke




ESUR/ESUI consensus statements on multi-parametric MRI for the detection of clinically significant prostate cancer: quality requirements for image acquisition, interpretation and radiologists' training

Maarten de Rooij¹  · Bas Israël^{1,2} · Marcia Tummers³ · Hashim U. Ahmed^{4,5} · Tristan Barrett⁶ · Francesco Giganti^{7,8} · Bernd Hamm⁹ · Vibeke Løgager¹⁰ · Anwar Padhani¹¹ · Valeria Panebianco¹² · Philippe Puech¹³ · Jonathan Richenberg¹⁴ · Olivier Rouvière^{15,16} · Georg Salomon¹⁷ · Ivo Schoots^{18,19} · Jeroen Veltman²⁰ · Geert Villeirs²¹ · Jochen Walz²² · Jelle O. Barentsz¹


Table 4 Consensus-based criteria ‘basic’ versus ‘expert’ radiologists. *N/A* not applicable

| Basic | Criterion | Expert |
|-------|-----------------------------------------------------------------|--------|
| 100 | Minimum number of supervised cases before independent reporting | N/A |
| 400 | Minimum number of cases read | 1000 |
| 150 | Minimum number of cases/year | 200* |
| 1 | Examination interval (year(s)) | 4 |
| 80 | Agreement in double reads with expert centre (%) | ≥ 90 |

THE RADIOLOGIST'S LEARNING CURVE FOR READING PROSTATE MRIS



The current prostate MRI reading workflow is lengthy, labour-intensive and requires substantial practice to master. Integrating AI in the prostate radiology workflow can increase its efficiency







CE marked | FDA cleared



- Accelerated workflow
- Accurate quantification
 - Elaborate reporting

Quantib® Connect solution





Prostate MRI Analysis powered by Quantib Prostate

ID pacienta: ██████████
 Meno pacienta: ██████████
 Dátum narodenia: 1962-04-30
 Dátum správy: 2022-09-29

Výsledky segmentácie prostaty



| Objem prostaty | PSA | Hustota PSA |
|----------------|---------|-------------|
| 25.8 ml | 5 ng/ml | 0.19 ng/ml |

Všeobecné nálezy

| Postihnutie lymfatickej uzliny | Kostné metastázy | Krvácanie | Prostatitída |
|--------------------------------|------------------|-----------|--------------|
| Áno | Možná | Možná | Nie |

Súhrn lézií

| Lézia | Stupeň PI-RADS | Najväčší axiálny rozmer | Umiestnenie PI-RADS |
|-------|----------------|-------------------------|---------------------|
| 1 | 4 | 2.15 cm | PZp/MN |

Komentár:
 This is a text report in Quantib

ID pacienta: 6254306185

Quantib Prostate 2.1.1 | Quantib AI Node 2.5.0

Strana 1 of 2

Lézia 1: PI-RADS 4

Bazálne PI-RADS 4 (T2-4, DWI 1, DCE: postihv)
 Umiestnenie PI-RADS PZp/MN

Najväčší axiálny rozmer: 2.15 cm (na axiálnom T2 reze: 1.7)



Objem: 3.241 ml
 ADC hodnoty (jednotky: vzájomného štandardu)

Extraprostatická rozšírenie: Možno
 Postihnutie sennových Áno
 vadoch

Postihnutie Možno
 neurovaskulárneho zväzku

Postihnutie močového Nie
 mechúra

Rez (rezy) na axiálnom T2: 8-15



Manuálna analýza prostaty schválil kvantibedmin on 2022-09-15 14:51:55

| Dátum štúdie | Výrobca zariadenia | Intenzita peča | Šifrovanie | Oprava série |
|--------------|--------------------|----------------|----------------------------|-----------------------|
| 2022-08-18 | Philips Healthcare | IT | 3011 DYNAMAC | 4021 DWI_40 3000-5000 |
| | | | 3011 c0_T2W_TSE_Ax | 4021 c0_T2W_TSE_Ax |
| | | | 3011 T2W_TSE_Sag_Isocenter | 4021 c0_T2W_TSE_Ax |
| | | | 3011 c0_T2W_TSE_Ax | 4021 gADC |

| Výrobca softvéru | Adresa | E-mail |
|------------------|--------------------------------------------------|------------------------------|
| Quantib B.V. | Westlaak 106, 3012 KM Rotterdam, The Netherlands | support-prostate@quantib.com |

ID pacienta: 6254306185



Quantib Prostate 2.1.1 | Quantib AI Node 2.5.0

Strana 1 of 2

Article

Quantib Prostate Compared to an Expert Radiologist for the Diagnosis of Prostate Cancer on mpMRI: A Single-Center Preliminary Study

Eliodoro Faiella ^{1,2}, Daniele Vertulli ¹, Francesco Esperto ³, Ermanno Cordelli ⁴, Paolo Soda ⁴, Rosa Maria Muraca ², Lorenzo Paolo Moramarco ², Rosario Francesco Grasso ¹, Bruno Beomonte Zobel ¹ and Domiziana Santucci ^{1,2,4,*}




Tomography 2022, 8, 2010–2019. <https://doi.org/10.3390/tomography8040168>

PSA density analysis mpMRI analysis

This workflow step is read-only, because it has been approved. Editing has been disabled.

⚠ There are 2 warnings
[Show more](#)

Editing tools



Reset segmentation Delete all ↶ ↷

Display

Show ROI as outlines [Reset viewers](#)



Measurements


PSA value: ng/ml

Prostate volume: 30.6 ml

PSA density: 0.34 ng/ml²

[Next >](#)

[Reject](#)  



PSA density analysis
mpMRI analysis

This workflow step is read-only, because it has been approved. Editing has been disabled.

There are 2 warnings [Show more](#)

Regions of interest

| Id | Volume ml | Dimension cm [slice] | ADC | PI-RADS |
|-----|-----------|----------------------|---------------|-----------|
| ● 1 | 2.690 | 1.86 [13] | 0.782 ± 0.217 | 5/PZpl-MR |

+

Editing tools



Finish editing








Delete all

← Previous

Approve

Reject





Prostate MRI Analysis
powered by Quantis Prostate

Id pacienta: _____ Miro pacienta: _____ Dáta: _____ Dáta spravy: _____

Výsledky segmentácie prostaty

| Objem prostaty | PSA | Podmienka PSA |
|----------------|------------|---------------|
| 30.4 ml | 0.53 ng/ml | 0.34 ng/ml |

Súhrn lézií

| Lézia | Stranovanie | Objem (ml) | PSA (ng/ml) | Ukážovacia hodnota |
|-------|-------------|------------|-------------|--------------------|
| 1 | S | 1.88 | 0.24 | P2pM1 |

Lézia 1: PI-RADS 5

Skórovane PI-RADS 4-7/2 s DWI & DCE: pozitívne
Ukážovacia PI-RADS P2pM1
Napätie 5.000 (rozdiel 1.88 na 100) axiálnom T2: pozitívne

Objem: 2.08 ml
ADC hodnota (pričítajú 0.782 x 0.237) (ng/ml): 0.24

Entropia: 0.000 (rozdiel 0.000 na 100) (ng/ml)

Prostata: 0.000 (rozdiel 0.000 na 100) (ng/ml)

Prostata: 0.000 (rozdiel 0.000 na 100) (ng/ml)

Prostata: 0.000 (rozdiel 0.000 na 100) (ng/ml)

Metabóla analýza prostaty schválená dňom: 2023-04-14 10:00:00

Dáta: 2023-04-14 | Vytvára: Prostate | Miesto: Prostate | Dáta spravy: 2023-04-14

Vytvára: Prostate | Adresa: Quantis Prostate, Inc. | E-mail: support.prostate@quantis.com



S podporou AI umožňuje hodnotenie mpMR na expertnej úrovni

- Zrýchľuje (zefektívňuje) hodnotenie
- Spresňuje a urýchľuje kvantifikáciu a hodnotenie
- Umožňuje efektívnu tvorbu štrukturovaného a štandardizovaného popisu